New York, February 05, 2013 -- Moody's Investors Services said that Catalent Pharma Solutions, Inc.'s ("Catalent") proposed term loan debt amendment is marginally positive since the savings from lower interest expense and extension of the debt maturity should boost Catalent's liquidity profile. However the amendment does not impact the B2 Corporate Family Rating or stable outlook. Existing debt ratings remain unchanged. The company announced plans to re-price its USD senior secured term loans, primarily to achieve lower pricing. Concurrently, the company will issue a $60 million add-on to its US dollar term loan due 2017 to refinance the remaining EUR term loan due 2014.

Vollständigen Artikel bei Moodys lesen